IMDX Insight Molecular Diagnostics Inc.

BULLISH Impact: 8/10 PRESS-RELEASE
Horizon months Filed Mar 26, 2026 Processed 2mo ago Wire GlobeNewswire
Press release: earnings
Latest settled — T+20d
IMDX ▲ +7.87% at T+20d
LONG call ✓ call won +7.87% · α vs SPY -4.88% · entry $3.56 → $3.84
Next anchor: T+60d in 13d
Last close $5.72 (close Jun 8) · +60.67% from $3.56 entry
Entry anchored
Mar 26, 03:59 PM ET
via Databento tick
T+1d
-28.37%
call -28.37% · α -28.01%
$2.55
settled 3mo ago
T+5d
-5.34%
call -5.34% · α -9.20%
$3.37
settled 2mo ago
T+20d
+7.87%
call +7.87% · α -4.88%
$3.84
settled 7w ago
T+60d
—
call — · α —
—
in 13d

Price Chart

Loading chart...

Executive Summary

Insight Molecular Diagnostics (IMDX) reported strong revenue growth for 2025, submitted its GraftAssureDx kidney transplant test for FDA review, and secured $26 million in financing to support commercialization and expansion into heart transplantation. Despite significant net losses, the company is transitioning toward commercialization with growing clinical engagement and favorable head-to-head data supporting its technology.

Key Financial Metrics

Revenue
$4.1M
+114.7% YoY
Adj. EPS
$-0.27
GAAP: $-0.72
Deal Value
$26.0M

Actionable Insight

The FDA submission and strong clinical traction suggest a potential inflection point. With cash now sufficient for 2+ years of operations and commercial launch expected in 2026, traders should monitor FDA feedback, kit sales conversion from engaged centers, and upcoming peer-reviewed publications on CM-score performance.

Key Facts

  • Submitted GraftAssureDx for FDA review on March 25, 2026 — first kitted dd-cfDNA assay under regulatory review for transplant rejection.
  • Completed $26 million registered direct offering in February 2026, netting $24.6 million to fund commercialization and R&D expansion.
  • Revenue grew 115% YoY to $4.1 million in 2025, with Q4 revenue at $1.1 million; gross margin improved to 56.7% from 39.3%.
  • Engaged with 37 U.S. transplant centers (over 25% of annual U.S. transplants) and 11 internationally via RUO and registry programs.
  • Second favorable head-to-head study vs. leading centralized test reinforces clinical differentiation and supports in-house adoption.
  • Non-GAAP net loss in Q4 2025 was $8.7 million ($0.27/share), significantly better than GAAP loss of $23.0 million ($0.72/share).
  • Cash balance post-financing is ~$37.5 million (Q4 cash of $12.9M + $24.6M net proceeds), funding operations into 2027.

Financial Impact

Revenue up 115% YoY to $4.1M; gross margin expanded 17.4 pts to 56.7%; $24.6M net cash raised; R&D up 62% to $15.9M

revenuegross_margincashr_d_expensenet_loss

Risk Factors

  • FDA review could be delayed if questions stop the 150-day clock.
  • Commercial adoption may lag despite clinical interest due to hospital procurement cycles.
  • High cash burn (~$7.5M/quarter expected in 2026) remains a concern if revenue ramp is slower than anticipated.

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3263407

US Market Status

Market Closed — Opens in 8h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access